Neuroprotective Effects of Olanzapine in N-Methyl-D-Aspartate-Induced Retinal Injury
dc.contributor.author | Onder, Halil Ibrahim | |
dc.contributor.author | Aktan, Gulderen | |
dc.contributor.author | Yuksel, Harun | |
dc.contributor.author | Avcioglu, Sedat | |
dc.contributor.author | Yildirim, Umran | |
dc.contributor.author | Kaya, Murat | |
dc.contributor.author | Tunc, Murat | |
dc.date.accessioned | 2024-04-24T17:08:02Z | |
dc.date.available | 2024-04-24T17:08:02Z | |
dc.date.issued | 2013 | |
dc.department | Dicle Üniversitesi | en_US |
dc.description.abstract | Purpose: The aim of this study was to investigate the neuroprotective effect of olanzapine (OLA), an atypical antipsychotic drug, on N-methyl-D-aspartate (NMDA)-induced retinal injury. Methods: Retinal neuronal ischemia was induced by NMDA in Wistar rats. OLA was administered intraperitoneally in 2 different dosages: 2 and 12 mg/kg. At the end of 2 weeks of OLA treatment, 1 eye of each animal was enucleated for histopathologic examination. We also measured malondialdehyde (MDA) levels in retinal homogenates as a marker of ischemic injury. Results: The retinal ganglion cell (RGC) count was significantly higher in cases where we used OLA 2 mg/kg or OLA 12 mg/kg compared to the control group (P = 0.0032 and P = 0.0005, respectively). We also found that MDA was significantly reduced by OLA 2mg/kg or OLA 12 mg/kg compared to the control group (P = 0.0001 and P = 0.0001, respectively). There was no statistically significant difference between OLA 2 mg/kg or OLA 12mg/kg groups in terms of RGC count and MDA levels (P > 0.05 for all). Conclusion: Our data showed that OLA preserved RGCs from NMDA-induced retinal injury; thus, it may have potential neuroprotective effects. | en_US |
dc.identifier.doi | 10.1089/jop.2012.0075 | |
dc.identifier.endpage | 430 | en_US |
dc.identifier.issn | 1080-7683 | |
dc.identifier.issn | 1557-7732 | |
dc.identifier.issue | 4 | en_US |
dc.identifier.pmid | 23215752 | en_US |
dc.identifier.scopus | 2-s2.0-84880526631 | en_US |
dc.identifier.scopusquality | Q2 | en_US |
dc.identifier.startpage | 427 | en_US |
dc.identifier.uri | https://doi.org/10.1089/jop.2012.0075 | |
dc.identifier.uri | https://hdl.handle.net/11468/17168 | |
dc.identifier.volume | 29 | en_US |
dc.identifier.wos | WOS:000318221900011 | en_US |
dc.identifier.wosquality | Q3 | en_US |
dc.indekslendigikaynak | Web of Science | |
dc.indekslendigikaynak | Scopus | |
dc.indekslendigikaynak | PubMed | |
dc.language.iso | en | en_US |
dc.publisher | Mary Ann Liebert, Inc | en_US |
dc.relation.ispartof | Journal of Ocular Pharmacology and Therapeutics | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | [No Keyword] | en_US |
dc.title | Neuroprotective Effects of Olanzapine in N-Methyl-D-Aspartate-Induced Retinal Injury | en_US |
dc.type | Article | en_US |